Author

Chang Gon Kim

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Initial Enfortumab Vedotin Dose Reduction and Outcomes in Pretreated Advanced Urothelial Carcinoma.

Importance Initial enfortumab vedotin (EV) dose selection is increasingly relevant in advanced urothelial carcinoma (UC). Reduced starting doses may be selected for some patients, but their associations with clinical outcomes and tolerability remain uncertain. Objective To evaluate the association of physician-select...

In-Ho Kim, Chang Gon Kim, Jungmin Jo et al. · JAMA Network Open · 0 citations

Open access Oct 2026

Real-World PSA Response and Safety Outcomes of 177Lu-PSMA-617 in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Validation Study

Background/Objectives: 177Lu-PSMA-617 is an established standard-of-care treatment for eligible patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Treatment schedules and follow-up in routine practice may differ from clinical trial protocols. Post-a...

Jin Hyeok Choi, Chang Gon Kim, K. T. Oh et al. · Journal of Clinical Medicine · 0 citations

Sep 2026

Parathyroid Carcinoma and Primary Hyperparathyroidism: Trends and Outcomes.

Parathyroid carcinoma is rare, and its epidemiological relationship to non-cancer primary hyperparathyroidism, along with the comparative long-term cardiometabolic burden of both conditions, remains poorly characterized at the population level. Using the Korea National Health Insurance Service database (2005-2020), we...

Seungjin Baek, M. Yu, Dong Wook Kim et al. · Endocrine-Related Cancer · 0 citations